4D Molecular Therapeutics Q2 net loss widens

4D Molecular Therapeutics

13/08/2026 21:24

Overview
US biotechnology firm's Q2 revenue rose and beat analyst expectations
Q2 net loss and operating income both missed analyst estimates
Company secured $200 mln credit facility from Hercules Capital, with $20 mln initially drawn

Outlook
Company expects topline data from 4D-150 4FRONT-1 Phase 3 in Q2 2027
Topline data from 4D-150 4FRONT-2 Phase 3 expected in H2 2027
4D-150 DME Phase 3 trial initiation planned for Q3 2026

Result Drivers
COLLABORATION REVENUE - Q2 revenue increase was mainly due to clinical trial cost sharing and reimbursement from Otsuka
R&D SPENDING - Higher research and development expenses were driven by execution of 4D-150 Phase 3 clinical trials in wet AMD
CREDIT FACILITY - Company secured $200 mln credit facility from Hercules Capital to provide strategic and operational flexibility

Company press release: ID:nGNX6mM9H2

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$3.78 mln
$3.10 mln (7 Analysts)
Q2 Net Loss
Miss
$72.94 mln
$70.25 mln (6 Analysts)
Q2 Operating Income
Miss
-$77.03 mln
-$74.25 mln (7 Analysts)
Q2 Loss Per Basic Share
 
$1.04
 
Q2 Operating Expenses
 
$80.81 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $31.00, about 161.2% above its August 12 closing price of $11.87

Reuters Recommended Reads
Aug 13 - Belite Bio Q2 net loss widens on higher expenses
Aug 11 - Eye care company Alcon raises margin outlook, shares jump
Aug 13 - ProQR Q2 revenue more than doubles

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)